2011
Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables
Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation 2011, 91: 1253-1261. PMID: 21519325, PMCID: PMC3145004, DOI: 10.1038/labinvest.2011.75.Peer-Reviewed Original ResearchConceptsCore needle biopsyCold ischemic timePre-analytic variablesNeedle biopsyEstrogen receptorIschemic timeTumor resectionTumor resection specimensAntigenic lossResection specimensTissue biomarkersTotal AktBiopsyPhospho-AktQuantitative immunofluorescencePhospho-ERKPhospho-S6K1Antigenic epitopesTotal ERKResectionTotal proteinCytokeratinImmunological methodsAntigenicitySignificant changes
2007
Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer
Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor–Positive Premenopausal Breast Cancer. Journal Of Clinical Oncology 2007, 25: 3007-3014. PMID: 17634479, DOI: 10.1200/jco.2006.08.9938.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBiopsy, NeedleBreast NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsEstrogen AntagonistsFemaleHumansImmunohistochemistryMiddle AgedMultivariate AnalysisPredictive Value of TestsPremenopauseProbabilityProportional Hazards ModelsReceptors, EstrogenRisk AssessmentSensitivity and SpecificitySurvival AnalysisTamoxifenConceptsEpidermal growth factor receptorER-positive patientsEGFR expressionBreast cancerEstrogen receptorTamoxifen-treated patientsEarly breast cancerRecurrence-free survivalRandomized clinical trialsLow EGFR expressionSignificant beneficial effectAdjuvant tamoxifenGrowth factor receptorEndocrine therapyTamoxifen responseTamoxifen treatmentClinical trialsSitu protein expressionUntreated groupTissue microarrayPatientsBeneficial effectsProtein expressionFactor receptorTreatment effects
2005
Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer
Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG, King BL. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Research 2005, 7: r1017. PMID: 16280052, PMCID: PMC1410733, DOI: 10.1186/bcr1335.Peer-Reviewed Original ResearchConceptsHigh-risk womenFluid-yielding ductsPrevious multicenter trialsMulticenter trialBreast cancerDuctal lavageLavage cellularityPresent seriesNAF productionSelective estrogen receptor modulatorsRisk-reducing therapiesRisk reduction therapyBRCA germline mutationsEstrogen receptor modulatorsBRCA-positive womenBreast cancer developmentEvaluation of abnormalitiesPostmenopausal statusHealthy womenBreast fluidIntraductal approachReceptor modulatorsRelative riskDuctal orificeReduction therapy
2002
Quantitative examination of mechanophysical tumor cell enrichment in fine‐needle aspiration specimens
Ernst LM, Rimm DL. Quantitative examination of mechanophysical tumor cell enrichment in fine‐needle aspiration specimens. Cancer 2002, 96: 275-279. PMID: 12378594, DOI: 10.1002/cncr.10746.Peer-Reviewed Original ResearchConceptsFine-needle aspirationBreast carcinomaMalignant cellsSurgical excisionHistologic sectionsDiagnostic fine needle aspirationNontumor cellsSurgical excision specimensChi-square testTumor cell enrichmentExcision specimensFNA specimensCurrent studyFNA specimenCarcinomaCDNA microarrayRepresentative slidesNonmalignant cellsThinPrep preparationsTotal cellsTissue sectionsCell enrichmentTumorsExcisionCellsp53 Mutations as Tumor Markers in Fine Needle Aspirates of Palpable Breast Masses
Dillon DA, Hipolito E, Zheng K, Rimm DL, Costa JC. p53 Mutations as Tumor Markers in Fine Needle Aspirates of Palpable Breast Masses. Acta Cytologica 2002, 46: 841-847. PMID: 12365217, DOI: 10.1159/000327057.Peer-Reviewed Original ResearchMeSH KeywordsAbscessAdenocarcinomaAdultAgedAged, 80 and overAmino Acid SubstitutionBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCarcinoma, Ductal, BreastCodon, TerminatorCystsDNA Mutational AnalysisDNA, NeoplasmExonsFemaleFrameshift MutationGenes, p53GenotypeHumansMiddle AgedMutationPolymorphism, Single-Stranded ConformationalRetrospective StudiesConceptsFine needle aspiratesP53 exons 5Breast massesPolymerase chain reactionNeedle aspiratesP53 mutationsSingle-strand conformational polymorphism analysisSubsequent excisional biopsyPalpable breast massesPotential diagnostic utilityDefinitive cytologic diagnosisTumor cell markersExon 5Molecular diagnostic markersExcisional biopsyBenign cytologyBreast carcinomaSuspicious cytologyRetrospective analysisCytologic diagnosisTumor markersDiagnostic criteriaBiopsy tissueMorphologic diagnosisDiagnostic utility
1998
Polymerase chain reaction‐based detection of clonality as a non‐morphologic diagnostic tool for fine‐needle aspiration of the breast
Magda J, Minger B, Rimm D. Polymerase chain reaction‐based detection of clonality as a non‐morphologic diagnostic tool for fine‐needle aspiration of the breast. Cancer 1998, 84: 262-267. PMID: 9723602, DOI: 10.1002/(sici)1097-0142(19980825)84:4<262::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original Research
1997
Comparison of the costs of fine‐needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis
Rimm D, Stastny J, Rimm E, Ayer S, Frable W. Comparison of the costs of fine‐needle aspiration and open surgical biopsy as methods for obtaining a pathologic diagnosis. Cancer 1997, 81: 51-56. PMID: 9100542, DOI: 10.1002/(sici)1097-0142(19970225)81:1<51::aid-cncr11>3.0.co;2-b.Peer-Reviewed Original Research